RecruitingPhase 2NCT05468372
Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
Studying Zygomycosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Intervention
- Posaconazole 600 mg followed by posaconazole 300 mg once daily(drug)
- Enrollment
- 50 target
- Eligibility
- 13 years · All sexes
- Timeline
- 2022 – 2025
Study locations (1)
- Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05468372 on ClinicalTrials.govOther trials for Zygomycosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07339800Chest CT Scan in Pulmonary Mucormycosis: Prognostic ValueUniversity Hospital, Strasbourg, France
- ACTIVE NOT RECRUITINGNCT07191756Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety StudyQiu Ye
- RECRUITINGNCT07185503Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and SafetyInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGNCT06515743Rehabilitation With an Obturator in Maxillary DefectsMenoufia University
- RECRUITINGNCT05406037Biomarkers for Invasive MucormycosisUniversity Hospital, Lille